Seeing injectable MS therapies differently: they are more similar than different.
Robert J
RJ
Fox
Douglas L
DL
Arnold
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D015415:Biomarkers / Q000032:analysis; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D005682:Gadolinium; D000068717:Glatiramer Acetate; D006801:Humans; D007267:Injections / Q000592:standards; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000592:standards; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010455:Peptides / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D005682:Gadolinium